Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bertotti

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Nature Biotechnology|October 12, 2021
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatinMartina Tedesco, Francesca Giannese, Dejan Lazarević, et al.
Genome Medicine|June 30, 2019
Evolving neoantigen profiles in colorectal cancers with DNA repair defectsGiuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, et al.
Molecular Systems Biology|May 26, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Molecular Systems Biology|April 14, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Cancer Research|June 11, 2025
Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype ParadigmErica A Oliveira, Salvatore Milite, Javier Fernandez-Mateos, et al.
Cell Reports|April 2, 2014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3Chong Sun, Sebastijan Hobor, Andrea Bertotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal CancerLuca Lazzari, Giorgio Corti, Gabriele Picco, et al.
Science Translational Medicine|August 16, 2023
Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancerRobin Beekhof, Andrea Bertotti, Franziska Böttger, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Science (New York, N.Y.)|November 9, 2019
Adaptive mutability of colorectal cancers in response to targeted therapiesMariangela Russo, Giovanni Crisafulli, Alberto Sogari, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Nature Biotechnology|October 12, 2021
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatinMartina Tedesco, Francesca Giannese, Dejan Lazarević, et al.
Genome Medicine|June 30, 2019
Evolving neoantigen profiles in colorectal cancers with DNA repair defectsGiuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, et al.
Molecular Systems Biology|May 26, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Molecular Systems Biology|April 14, 2019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinasesRobin Beekhof, Carolien van Alphen, Alex A Henneman, et al.
Cancer Research|June 11, 2025
Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype ParadigmErica A Oliveira, Salvatore Milite, Javier Fernandez-Mateos, et al.
Cell Reports|April 2, 2014
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3Chong Sun, Sebastijan Hobor, Andrea Bertotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal CancerLuca Lazzari, Giorgio Corti, Gabriele Picco, et al.
Science Translational Medicine|August 16, 2023
Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancerRobin Beekhof, Andrea Bertotti, Franziska Böttger, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Science (New York, N.Y.)|November 9, 2019
Adaptive mutability of colorectal cancers in response to targeted therapiesMariangela Russo, Giovanni Crisafulli, Alberto Sogari, et al.
Pageof 10